Clinical Trial Detail

NCT ID NCT02754856
Title Tremelimumab (Anti-CTLA-4) Plus MEDI4736 (Anti-PD-L1) in Resectable Colorectal Cancer Liver Metastases.
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

colorectal cancer

Therapies

Bevacizumab + Durvalumab + Fluorouracil + Leucovorin + Oxaliplatin + Tremelimumab

Age Groups: adult

No variant requirements are available.